Menu
Your Cart

Apostle MiniEnrich Hybrid Capture Reagents v2, 16 rxn

Apostle MiniEnrich Hybrid Capture Reagents v2, 16 rxn
Secured Shopping
Best security features
Apostle MiniEnrich Hybrid Capture Reagents v2, 16 rxn

Introduction

Apostle MiniEnrich Hybrid Capture Reagents v2 is designed for targeted enrichment of small Panel and hybrid capture of various types of pre-libraries, integrated with upgraded and optimized hybrid capture and elution processes, and equipped with Apostle MiniEnrich Panel designed based on innovative protocols, which can complete the whole process of capture-library preparation in same day.

 

Feature

o   Precise detection of large-scale CpG sites: Simultaneously assessment of multiple genes' CpG sites associated with various cancers, achieving precise comprehensive joint testing

o   Accurate quantification of methylation levels: High-precision coverage for accurate quantification of different methylation states ranging from 0 to 100% in various samples

o   Fast and convenient operation: Simplified experimental procedures, and user-friendly operations, completing the entire process within same day

o   Highly efficient and stable: Avoid inconsistent amount of raw data, ensuring stability in capture sequencing results, thereby reducing the risk of rework

o   Cost-effective sequencing: Utilize a mixed hybrid mode to reduce the quantity of hybrid reaction, lower sequencing costs and enhance cost-effectiveness


Information

Cat #

NA004321

Capacity

16 rxn

Performance

Check information page

Protocol


$400.00
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.